5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of Flavored Tobacco Use With Tobacco Initiation and Subsequent Use Among US Youth and Adults, 2013-2015

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What is the association between first flavored use of a given tobacco product and subsequent tobacco use, including progression of tobacco use, among US youth (aged 12-17 years), young adults (aged 18-24 years), and adults (aged ≥25 years)?

          Findings

          In this cohort study of 11 996 youth and 26 447 adults who participated in waves 1 and 2 of the Population Assessment of Tobacco and Health Study, most youth and young adult new tobacco users first tried a flavored product. First use of flavored tobacco products was positively associated with subsequent product use compared with first use of a nonflavored product.

          Meaning

          First use of flavored tobacco products may place youth and adults at risk of subsequent tobacco use.

          Abstract

          This cohort study uses data from the Population Assessment of Tobacco and Health (PATH) Study to examine whether first use of flavored tobacco products is associated with subsequent tobacco use among US youth and adults.

          Abstract

          Importance

          Flavors in tobacco products may appeal to young and inexperienced users.

          Objective

          To examine among youth (aged 12-17 years), young adults (aged 18-24 years), and adults (aged ≥25 years) the prevalence of first use of flavored tobacco products among new tobacco users and the association between first flavored use of a given tobacco product and tobacco use 1 year later, including progression of tobacco use.

          Design, Setting, and Participants

          This cohort study represents a longitudinal analysis of data from the Population Assessment of Tobacco and Health (PATH) Study, a nationally representative study with data collected in 2013 to 2014 (wave 1) and 2014 to 2015 (wave 2). Participants were noninstitutionalized individuals, including 11 996 youth and 26 447 adults, in selected households who participated in both waves of the PATH Study. Data analysis was conducted from July 2016 to June 2019.

          Main Outcomes and Measures

          Prevalence of tobacco product use at wave 2.

          Results

          The mean (SE) age of the participants was 14.5 (0.0) years for youth, 21.1 (0.0) years for young adults, and 50.3 (0.0) for adults. Most youth (71.9%; 95% CI, 69.7%-74.0%) and young adults (57.6%; 95% CI, 54.9%-60.3%) who were new users of tobacco products over the 10- to 13-month follow-up period used flavored products. First use of a menthol or mint or other flavored cigarette documented at wave 1 was positively associated with past 12-month and past 30-day cigarette use in all age groups at wave 2 compared with first use of a nonflavored cigarette (youth, flavored cigarette, past 12-month use adjusted prevalence ratio [aPR], 1.14 [95% CI, 1.05-1.25] and past 30-day use aPR, 1.15 [95% CI, 1.00-1.31]; youth, menthol or mint cigarette, past 12-month use aPR, 1.18 [95% CI, 1.08-1.29] and past 30-day use aPR, 1.19 [95% CI, 1.04-1.37]; young adult, flavored cigarette, past 12-month use aPR, 1.09 [95% CI, 1.04-1.15] and past 30-day use aPR, 1.13 [95% CI, 1.06-1.21]; young adult menthol or mint cigarette, past 12-month use aPR, 1.10 [95% CI, 1.05-1.16] and past 30-day use aPR, 1.15 [95% CI, 1.07-1.23]; adult flavored cigarette, past 12-month use aPR, 1.10 [95% CI, 1.05-1.15] and past 30-day use aPR, 1.09 [95% CI, 1.04-1.14]; adult menthol or mint cigarette, past 12-month use aPR, 1.13 [95% CI, 1.08-1.18] and past 30-day use aPR, 1.12 [95% CI, 1.07-1.17]). Among young adults, first use of flavored e-cigarettes (aPR, 2.05; 95% CI, 1.61-2.61), any cigars (aPR, 1.60; 95% CI, 1.26-2.02), cigarillos (aPR, 1.49; 95% CI, 1.08-2.05), filtered cigars (aPR, 3.69; 95% CI, 2.08-6.57), hookah (aPR, 1.91; 95% CI, 1.23-2.98), and any smokeless tobacco (aPR, 1.54; 95% CI, 1.08-2.20) was prospectively associated with current regular use of those products at wave 2 compared with first nonflavored use. Among adults aged 25 years and older, first use of flavored e-cigarettes (aPR, 1.60; 95% CI, 1.41-1.82), any cigars (aPR, 1.56; 95% CI, 1.29-1.87), cigarillos (aPR, 1.29; 95% CI, 1.01-1.64), filtered cigars (aPR, 1.79; 95% CI, 1.25-2.54), hookah (aPR, 5.66; 95% CI, 2.04-15.71), and any smokeless tobacco (aPR, 1.55; 95% CI, 1.32-1.82) was prospectively associated with current regular use of those products at wave 2 compared with first nonflavored use.

          Conclusions and Relevance

          In this longitudinal cohort study, flavors in tobacco products were associated with youth and young adult tobacco experimentation. First use of a flavored tobacco product may place youth, young adults, and adults at risk of subsequent tobacco use.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Tobacco-Product Use by Adults and Youths in the United States in 2013 and 2014.

          Noncigarette tobacco products are evolving rapidly, with increasing popularity in the United States.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Flavored Tobacco Product Use in Youth and Adults: Findings From the First Wave of the PATH Study (2013–2014)

            The 2009 Family Smoking Prevention and Tobacco Control Act banned characterizing flavors other than menthol in cigarettes but did not restrict their use in other forms of tobacco (e.g., smokeless, cigars, hookah, e-cigarettes).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Development and validation of the GAIN Short Screener (GSS) for internalizing, externalizing and substance use disorders and crime/violence problems among adolescents and adults.

              The Global Appraisal of Individual Needs (GAIN)1 is a 1-2 hour standardized biopsychosocial that integrates clinical and research assessment for people presenting to substance abuse treatment. The GAIN - Short Screener (GSS) is 3-5 minute screener to quickly identify those who would have a disorder based on the full 60-120 minute GAIN and triage the problem and kind of intervention they are likely to need along four dimensions (internalizing disorders, externalizing disorders, substance disorders, and crime/violence). Data were collected from 6,177 adolescents and 1,805 adults as part of 77 studies in three dozen locations around the United States that used the GAIN. For both adolescents and adults the 20-item total disorder screener (TDScr) and its four 5-item sub-screeners (internalizing disorders, externalizing disorders, substance disorders, and crime/violence) has good internal consistency (alpha of .96 on total screener), is highly correlated (r = .84 to .94) with the 123-item longer scales in the full GAIN. The GSS also does well in terms of its receiver operator characteristics (90% or more under the curve in all analyses) and has clinical decision-making cut points with excellent sensitivity (90% or more) for identifying people with a disorder and excellent specificity (92% or more) for correctly ruling out people who did not have a disorder. The GSS has good potential as an efficient screener for identifying people with co-occurring disorders across multiple systems and routing them to the right services and more detailed assessments.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                23 October 2019
                October 2019
                23 October 2019
                : 2
                : 10
                : e1913804
                Affiliations
                [1 ]The Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative, Washington, DC
                [2 ]Vermont Center on Behavior and Health, Department of Psychiatry, The University of Vermont, Burlington
                [3 ]Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland
                [4 ]Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, Bethesda, Maryland
                [5 ]Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston
                [6 ]Westat, Rockville, Maryland
                [7 ]Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
                [8 ]Department of Health Education and Behavioral Science, Center for Tobacco Studies, Rutgers School of Public Health, Piscataway, New Jersey
                [9 ]Department of Health Behavior, Division of Cancer Prevention & Population Sciences, Roswell Park Cancer Institute, Buffalo, New York
                [10 ]Kelly Government Solutions, Rockville, Maryland
                Author notes
                Article Information
                Accepted for Publication: September 5, 2019.
                Published: October 23, 2019. doi:10.1001/jamanetworkopen.2019.13804
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Villanti AC et al. JAMA Network Open.
                Corresponding Author: Andrea C. Villanti, PhD, MPH, Vermont Center on Behavior and Health, Department of Psychiatry, University of Vermont, 1 S Prospect St, MS 482, Burlington, VT 05401 ( andrea.villanti@ 123456uvm.edu ).
                Author Contributions: Dr Villanti and Ms Johnson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Villanti, Johnson, Glasser, Rose, Conway, Cummings, Wackowski, Feirman, Bernat, Silveira.
                Acquisition, analysis, or interpretation of data: Villanti, Johnson, Glasser, Rose, Ambrose, Stanton, Edwards, Delnevo, Wackowski, Bansal-Travers, Holder-Hayes, Green, Silveira, Hyland.
                Drafting of the manuscript: Villanti, Johnson, Glasser, Delnevo, Silveira.
                Critical revision of the manuscript for important intellectual content: Villanti, Johnson, Rose, Ambrose, Conway, Cummings, Stanton, Edwards, Delnevo, Wackowski, Feirman, Bansal-Travers, Bernat, Holder-Hayes, Green, Silveira, Hyland.
                Statistical analysis: Johnson, Glasser, Edwards, Wackowski.
                Obtained funding: Ambrose, Hyland.
                Administrative, technical, or material support: Villanti, Johnson, Glasser, Rose, Ambrose, Stanton, Edwards, Bansal-Travers, Bernat, Green, Hyland.
                Supervision: Villanti, Conway, Feirman
                Conflict of Interest Disclosures: Ms Johnson reported receiving grants and personal fees from Westat and the Population Assessment of Tobacco and Health Study during the conduct of the study. Dr Cummings reported receiving grant funding from Pfizer, Inc, to study the impact of a hospital-based tobacco cessation intervention and reported receiving funding as an expert witness in litigation filed against the tobacco industry. Dr Delnevo reported receiving grants from Rutgers Center for Tobacco Studies during the conduct of the study outside the submitted work. Dr Wackowski reported receiving grants from the National Institutes of Health and the US Food and Drug Administration Center for Tobacco Products outside the submitted work. This article was prepared while Dr Conway was employed at the National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. No other disclosures were reported.
                Funding/Support: This work was supported by the National Institute on Drug Abuse, National Institutes of Health, and the Center for Tobacco Products, US Food and Drug Administration, Department of Health and Human Services, under contract HHSN271201100027C to Westat.
                Role of the Funder/Sponsor: Representatives from the National Institute on Drug Abuse and the US Food and Drug Administration contributed to the interpretation of the data and participated in the preparation, review, and approval of the manuscript.
                Disclaimer: The views and opinions expressed in this manuscript are those of the authors only and do not necessarily represent the views, official policy, or position of the US Department of Health and Human Services or any of its affiliated institutions or agencies.
                Article
                zoi190526
                10.1001/jamanetworkopen.2019.13804
                6820032
                31642927
                8eedc95c-683a-4878-83bf-53a283887db6
                Copyright 2019 Villanti AC et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 15 February 2019
                : 5 September 2019
                Categories
                Research
                Original Investigation
                Featured
                Online Only
                Public Health

                Comments

                Comment on this article

                scite_

                Similar content538

                Cited by49

                Most referenced authors424